TD Cowen Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300

Benzinga · 08/04 16:30
TD Cowen analyst Joseph Thome maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $275 to $300.